等待开盘 06-26 09:30:00 美东时间
+0.130
+2.88%
Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $70.000 million-$73.000 million to $70.000 million-$73.000 million vs $71.267 million estimate.
05-11 20:03
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Exagen Inc. appoints Dr. Michael Mahler as Chief Scientific Officer. With a strong background in immunology, Mahler, who earned his Ph.D. at the University of Heidelberg and previously served at Werfen, brings extensive expertise in autoimmune research and diagnostics. His addition aims to strengthen Exagen's diagnostic capabilities and patient care advancements.
2025-06-23 13:00
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.26) by 23.08 percent. This is a 35.48 percent increase over losses of $(0.31) per share from the same
2025-03-11 20:00
Companies Reporting Before The Bell • Exagen (NASDAQ:XGN) is projected to repor...
2025-03-11 16:32